Efficacy and safety of lemborexant in subjects with insomnia disorder receiving medications for depression or anxiety symptoms
LEM treatment benefited subjects with insomnia treated with medications for depression/anxiety symptoms, with no new safety signals. A greater placebo response in the subpopulation than in the overall population decreased the drug versus placebo effect size for LEM, as has been reported for other insomnia medications.
Authors
- Jane Yardley (ORCID: https://orcid.org/0000-0001-8198-4328)
- Manoj Malhotra (ORCID: https://orcid.org/0000-0002-4315-8284)
- Pierre Blier (ORCID: https://orcid.org/0000-0002-9196-0706)
- Andrew A. Nierenberg (ORCID: https://orcid.org/0000-0003-2897-0458)
- Andrew D. Krystal (ORCID: https://orcid.org/0000-0002-6702-781X)
- Yoshikazu Takaesu (ORCID: https://orcid.org/0000-0002-9169-3249)
- Larry Culpepper (ORCID: https://orcid.org/0000-0002-7655-0477)
- Kate Pinner (ORCID: https://orcid.org/0000-0002-3475-2708)
- Margaret L. Moline (ORCID: https://orcid.org/0000-0003-0807-2167)
- Naoki Kubota (ORCID: https://orcid.org/0000-0002-1292-0897)
Institutions
- Boston University (US)
- Harvard University (US)
- University of California, San Francisco (US)
- Royal Ottawa Mental Health Centre (CA)
- University of the Ryukyus (JP)
- Massachusetts General Hospital (US)
- Eisai (United Kingdom) (GB)
- Eisai (United States) (US)
- Eisai (Japan) (JP)
Publication Details
- Journal
- Neuropsychopharmacology Reports
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1002/npr2.12509
- Citations
- 2
- Primary Topic
- Sleep and related disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.02
Funders
- Eisai Canada